Management of hereditary ovarian cancer;A családi halmozódású petefé szekrák genetikai és onkológiai ellátása

Orvosi Hetilap

Volumn 152, Issue 40, 2011, Pages 1596-1608

  Joó, József Gábor ^a,d   Ládi, Szabolcs ^b   Nagy, B Zsolt ^b   Langmár, Zoltán ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NAGY GEN Diagnosztikai es Kutatasi Kft   (Hungary)

^c Fovarosi Szent Istvan es Szent Laszlo Korhaz   (Hungary)

^d NONE   (Hungary)

Author keywords

BRCA gene; diagnosis; hereditary; mutation; ovarian carcinoma; treatment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM;

ARTICLE; CANCER THERAPY; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; GENE MUTATION; HEREDITY; HUMAN; OVARY CANCER; RETROSPECTIVE STUDY;

EID: 80053370407     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2011.29218     Document Type: Article

References (78)

1. World Health Organization: World Health Organization Statistics. 2008.
2. Risch, H. A., McLaughlin, J. R., Cole, D. E. C. Ésmtsai: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin cohort study in Ontario, Canada. J. Natl. Cancer Inst., 2006, 98, 1694-1706. (Pubitemid 44942707)
3. Drew, Y., Calvert, H.: The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann. N.Y. Acad. Sci., 2008, 1138, 136-145.
4. Cook, J.: Family history of ovarian cancer. Curr. Obstet. Gynecol., 2002, 12, 47-51. (Pubitemid 34031424)
5. Malkin, D., Li, F. P., Strong, L. C. Ésmtsai: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science, 1990, 250, 1233-1238. (Pubitemid 120031831)
6. Lynch, E. D., Ostermeyer, E. A., Lee, M. K. Ésmtsai: Inherited mutations in PTEN that are associated with breast cancer, Cowden disease and juvenile polyposis. Am. J. Hum. Genet., 1997, 61, 1254-1260. (Pubitemid 28046900)
7. Renwick, A., Thompson, D., Seal, S. Ésmtsai: ATM mutations that cause ataxia teleangiectasia are breast cancer susceptibiltiy alleles. Nat. Genet., 2006, 38, 873-875. (Pubitemid 44141653)
8. Giardello, F. M., Brensinger, J. D., Tersmette, A. C. Ésmtsai: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 2000, 119, 1447-1453. (Pubitemid 32198669)
9. Kasprzak, L., Foulkes, W. D., Shelling, A. N.: Hereditary ovarian carcinoma. Br. Med. J., 1999, 318, 786-789.
10. Barroso, E., Milne, R. L., Fernandez, L. P. Ésmtsai: FANC2D associated with sporadic breast cancer. Carcinogenesis, 2006, 27, 1930-1937. (Pubitemid 44307832)
11. Aarnio, M., Mecklin, J., Aaltonen, L. A. Ésmtsai: Lifetime risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer, 1995, 64, 430-433. (Pubitemid 26048907)
12. Quaye, L., Tyrer, J., Ramus, S. J. Ésmtsai: Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer. PLoS One, 2009, 4, e5983, 1-7.
13. Ramus, S. J., Vierkant, R. A., Johnatty, S. E. Ésmtsai: Consortium analysis of 7 candidate SNPs for ovarian cancer. Int. J. Cancer, 2008, 123, 380-388. (Pubitemid 351842023)
14. Palmieri, R. T., Wilson, M. A., Iversen, E. S. És mtsai: Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 3567-3572.
15. Shen, J., Ambrosone, C. B., DiCiccio, R. A. Ésmtsai: A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis, 2008, 29, 1963-1966.
16. Hoskins, K. F., Stopfer, J. E., Calzone, K. A. Ésmtsai: Assessment and counselling for women with a family history of breast cancer: a guide for clinicians. JAMA, 1995, 273, 577-585.
17. Olopade, O. I., Pichert, G.: Cancer genetics in oncology practice. Ann. Oncol., 2001, 12, 895-908. (Pubitemid 32725760)
18. Hildreth, N. G., Kelsey, J. L., LiVolsi, V. A. Ésmtsai: An epidemiologic study of the epithelial ovarian cancer. Am. J. Epidemiol., 1981, 114, 398-405. (Pubitemid 11003786)
19. Mori, M., Harabuchi, I., Miyake, H. Ésmtsai: Reproductive, genetic and dietary risk factors for ovarian cancer. Am. J. Epidemiol., 1988, 128, 771-777.
20. Franceschi, S., Parazzini, F., Negri, E. Ésmtsai: Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int. J. Cancer, 1991, 49, 61-65.
21. Adami, H. O., Hsieh, C. C., Lambe, M. Ésmtsai: Parity, age at fi rst childbirth, and risk of ovarian cancer. Lancet, 1994, 344, 1250-1254.
22. Parkin, D. M., Whelan, S. L., Ferlay, J. Ésmtsai: Cancer Incidence in Five Continents. Vol. VII. IARC Scientifi c Publications, Lyon, 1997.
23. Hartge, P., Whittemore, S., Itnyre, J. Ésmtsai: Rates and risks of ovarian cancer in subgroups of white women in the United States. Obstet. Gynecol., 1994, 84, 760-764. (Pubitemid 24329840)
24. Schildkraut, J. M., Risch, N., Thompson, W. D. Ésmtsai: Evaluating genetic association among ovarian, breast and endometrial cancer: evidence for a breast/ovarian cancer relationship. Am. J. Hum. Genet., 1989, 45, 521-529. (Pubitemid 19261439)
25. Houlston, R. S., Bourne, T. H., Collins, W. P. és mtasi: Risk of ovarian cancer and genetic relationship to other cancer families. Hum. Hered., 1993, 43, 111-115. (Pubitemid 23098547)
26. Moslehi, R., Chu, W., Karlan, B. Ésmtsai: BRCA1 and BRCA2 mutation analysis of 208 Askhenazi Jewish women with ovarian cancer. Am. J. Hum. Genet., 2000, 66, 1259-1272. (Pubitemid 30468783)
27. Jishi, M. F., Itnyre, J. H., Oakley-Girvan, I. A. Ésmtsai: Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Cancer, 1995, 76, 1416-1421.
28. Liber, A. F.: Ovarian cancer in a mother and five daughters. Arch. Pathol., 1950, 49, 280-290.
29. Go, R. C., King, M. C., Bailey-Wilson, J. Ésmtsai: Genetic epidemiology of breast cancer and associated cancers in high-risk families. I. Segregeation analysis. J. Natl. Cancer Inst., 1983, 71, 455-461. (Pubitemid 13012119)
30. Miki, Y., Swensen, J., Shattuck-Eidens, D. Ésmtsai: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994, 266, 66-71. (Pubitemid 24345325)
31. Wooster, R., Bignell, G., Lancaster, J. Ésmtsai: Identifi cation of the breast cancer susceptibility gene BRCA2. Nature, 1995, 378, 789-792. (Pubitemid 26004412)
32. Roth, S., Kristo, P., Auranen, A. Ésmtsai: A missense mutation in the BRCA2 gene in three siblings with ovarian cancer. Br. J. Cancer, 1998, 77, 1199-1202. (Pubitemid 28140605)
33. Vasen, H. F., Mecklin, J. P., Khan, P. M. Ésmtsai: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis. Colon Rectum, 1991, 34, 424-425.
34. Russo, A., Calo, V., Bruno, I. es mtsai: Hereditary ovarian cancer. Crit. Rev. Oncol. Hematol., 2009, 69, 28-44.
35. Lancaster, J. M., Powell, C. B., Kauff, N. D. Ésmtsai: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol. Oncol., 2007, 107, 159-162. (Pubitemid 47575743)
36. Buermeyer, A. B., Deschenes, S. M., Baker, S. M. Ésmtsai: Mammalian DNA mismatch repair. Annu. Rev. Genet., 1999, 33, 533-564. (Pubitemid 30083132)
37. Bewtra, C., Watson, P., Conway, T. Ésmtsai: Hereditary ovarian cancer: a clinicopathological study. Int. J. Gynecol. Pathol., 1992, 11, 180-187.
38. Muto, M. G., Cramer, D. W., Tangir, J. Ésmtsai: Frequency of the BRCA1 185delAG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res., 1996, 56, 1250-1252. (Pubitemid 26080964)
39. Tonin, P. M., Mes-Masson, A. M., Narod, S. A. Ésmtsai: Founder BRCA1 and BRCA2 mutations in French-Canadian ovarian cancer cases unselected for family history. Clin. Genet., 1999, 55, 318-324. (Pubitemid 29295324)
40. Mahle, L., Apold, J., Paulsen, T. Ésmtsai: High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin. Canc. Res., 2008, 14, 7569-7573.
41. Piver, M. S., Baker, T. R., Jishi, M. F. Ésmtsai: Familial ovarian cancer. A report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981-1991. Cancer, 1993, 71, 582-588. (Pubitemid 23021254)
42. Lakhani, S. R., Manek, S., Penault-Llorca, F. Ésmtsai: Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Canc. Res., 2004, 10, 2473-2481. (Pubitemid 38445709)
43. Fathalla, M. F.: Incessant ovulation - a factor in ovarian neoplasia? Lancet, 1971, 2, 163.
44. Rubin, C., Benjamin, I., Behbakht, K. Ésmtsai: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA. N. Engl. J. Med., 1996, 335, 1413-1416. (Pubitemid 26382501)
45. Piver, M. S.: Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial 64. Ovarian Cancer Registry. Gynecol. Oncol., 2002, 85, 9-17. (Pubitemid 34304004)
46. Teneriello, M., Park, R. C.: Early detection of ovarian cancer. CA Cancer J. Clin., 1995, 45, 71-87.
47. Nguyen, N. H., Averette, H. E., Hoskins, W. Ésmtsai: Natural survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Obstetrics and Gynecology Staging system. Cancer, 1993, 72, 3007-3011. (Pubitemid 23335048)
48. Karlan, B. Y., Baldwin, R. L., Lopez-Luevanos, E. Ésmtsai: Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am. J. Obstet. Gynecol., 1999, 180, 917-928. (Pubitemid 29200558)
49. Bell, R., Luengo, S., Petticrew, M. Ésmtsai: Screening for ovarian cancer: a systematic review. Health Technol. Assess., 1998, 2, 1-84.
50. Jacobs, I., Oram, D.: Screening for ovarian cancer. Biomed. Pharmacother., 1988, 42, 589-596. (Pubitemid 19033374)
51. Van Nagel, J. R. Jr., Gallion, H. H., Pavlik, E. J. és mtsa: Ovarian cancer screening. Cancer, 1995, 76 (10 Suppl.), 2086-2091.
52. Van Nagel, J. R. Jr., DePriest, P. D., Reedy, M. B. Ésmtsai: The effi cacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol., 2000, 77, 350-356. (Pubitemid 30368549)
53. Pavlik, E. J., DePriest, P. D., Gallion, H. H. Ésmtsai: Ovarian volume related to age. Gynecol. Oncol., 2000, 77, 410-412. (Pubitemid 30368559)
54. DePriest, P. D., Varner, E., Powell, J. Ésmtsai: The effi cacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol. Oncol., 1994, 55, 174-178. (Pubitemid 24366622)
55. Carter, J. R., Lau, M., Fowler, J. M. Ésmtsai: Blood fl ow characteristics of ovarian tumours: implications for early detection for ovarian cancer screening. Am. J. Obstet. Gynecol., 1995, 72, 901-907.
56. Predanic, M., Vlahos, N., Pennisi, J. A. Ésmtsai: Color and pulsed Doppler sonography, grey-scale imaging and serum CA 125 in the assessment of adnexal disease. Obstet. Gynecol., 1996, 88, 283-288. (Pubitemid 26250307)
57. Bourne, T. H., Campbell, S., Reynolds, K. M. Ésmtsai: Screening for early ovarian cancer with transvaginal ultrasonography and colour blood fl ow imaging. Br. Med. J., 1993, 306, 1025-1029. (Pubitemid 23105959)
58. Campbell, S., Bhan, V., Royston, P. Ésmtsai: Transabdominal ultrasound screening for ovarian cancer. Br. Med. J., 1989, 299, 1363-1367. (Pubitemid 20005300)
59. Bast, R., Klug, T. L., St. John, E. Ésmtsai: Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest., 1981, 68, 1331-1337.
60. Zurawski, V., Orjaseter, H., Andersen, A. Ésmtsai: Elevated serum CA-125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int. J. Cancer, 1988, 42, 677-680. (Pubitemid 19008906)
61. Jacobs, I., Bast, R. C. Jr.: The CA-125 tumour-associated antigen: a review of the literature. Hum. Reprod., 1989, 4, 1-12. (Pubitemid 19069900)
62. Medeiros, L. R., Dornelles Rosa, D., da Rosa, M. I. Ésmtsai: Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 142, 99-105.
63. Skates, S. J., Xu, F. J., Yu, Y. H. Ésmtsai: Toward an optimal algorhythm for ovarian cancer screening with longitudinal tumor markers. Cancer, 1995, 76 (10 Suppl.), 2004-2010.
64. Moore, R. G., MacLaughlan, S., Bast, R. C. Jr.: Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol. Oncol., 2010, 116, 240-245.
65. www.myriadtest.com
66. Frank, T. S., Manley, S. A., Olopade, O. I. Ésmtsai: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J. Clin. Oncol., 1998, 16, 2417-2425. (Pubitemid 28309036)
67. Wakahara, F., Kikkawa, F., Nawa, A. Ésmtsai: Diagnostic efficacy of tumor markers, sonography and intraoperative frozen section for ovarian tumors. Gyn. Obstet. Invest., 2001, 52, 147-152. (Pubitemid 34701703)
68. Despierre, E., Lambrechts, D., Neven, P. Ésmtsai: The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol. Oncol., 2010, 117, 358-365.
69. Hall, J., Paul, J., Brown, R.: Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev. Mol. Med., 2004, 6, 1-20. (Pubitemid 43118253)
70. Obata, K., Morland, S. J., Watson, R. H. Ésmtsai: Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 1998, 58, 2095-2097. (Pubitemid 28232892)
71. Kurman, R. J., Shih, I. M.: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol., 2008, 27, 151-160. (Pubitemid 351450677)
72. Singer, G., Stohr, R., Cope, L. Ésmtsai: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and highgrade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol., 2005, 29, 218-224. (Pubitemid 40170640)
73. Barton, C. A., Hacker, N. F., Clark, S. J. Ésmtsai: DNA methylation changes in ovarian cancer: implication for early diagnosis, prognosis and treatment. Gynecol. Oncol., 2008, 109, 129-139.
74. Couzin, J.: MicroRNAs make big impression in disease after disease. Science, 2008, 319, 1782-1784. (Pubitemid 351451552)
75. Zhang, L., Huang, J., Yang, N. Ésmtsai: MicroRNAs exhibit high frequency genomic alterations in human cancers. Proc. Natl. Acad. Sci. USA, 2008, 105, 13021-13026.
76. Quinn, J. E., Carser, J. E., James, C. R. Ésmtsai: BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol. Oncol., 2009, 113, 134-142.
77. Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y. Ésmtsai: Gene expression profi le of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol., 2010, 28, 3555-3561.
78. Erratum in: J. Clin. Oncol., 2010, 28, 4868.